- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02900963
Nutritional Status Assessment in Head and Neck Cancer Patients Receiving Radiotherapy or Chemo-radiotherapy (NUTRINECK)
Nutritional Assessment of Locally Advanced Head and Neck Cancer Patients Who Underwent Exclusive or Adjuvant Radiotherapy or Chemo-radiotherapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Head and neck cancer is one of the most common malignancies in the world, Malnutrition occurs frequently at the time of diagnosis as consequences of alcohol consumption and tobacco use that is quite common in this patients population, and of local tumor invasion, obstructing the function of swallowing and chewing. In addition, during the treatment, mucositis, anorexia, dysphagia, mouth sores, and other acute and late toxic effects of radiotherapy (RT) and chemotherapy frequently worsen the nutritional status.
Poor nutritional status and chemotherapy or RT-toxicity, lead to treatment interruption frequently and is also associated with higher risk of infection, hospital readmission, early death, worse survival outcomes, and deterioration in the quality of life (QoL). According to published results, one third of the patient would have benefit from a complete treatment. In addition, the correlation exists between some biological parameters (CRP, albumin, neutrophils, Hb) and the nutritional status. Therefore, it deems essential to maintain nutritional status in head and neck cancer patients undergoing RT and chemotherapy.
Dietary counseling and oral supplements showed positive influences on nutritional outcomes and QoL However, their role is limited when it comes to obstruction or mucositis. Thus, enteral feeding may be a choice either through nasogastric tube (NGT) or percutaneous endoscopic gastrostomy (PEG). Studies investigated the effects of PEG compared with NGT were not conclusive or showing no consistent results on nutritional status, treatment interruption, nutrition-related hospital admission, and tube-related complications in the head and neck cancer patients receiving RT or chemo-radiotherapy.
The optimal method and the timing of placement are still debated. Consequently, the aim of this study is to collect data on our current daily practice on supplementary nutrition method ( NGT, PEG) in head and neck cancers patients treated in our radiation therapy unit and to identify factors predicting good treatment outcomes( ie full treatment administration).
Secondary objectives are to collect nutritional data during the treatment, to study the nutritional status in relation to acute or late adverse events, to study the impact of an early enteral feeding on clinical and biological parameters.
Ancillary study: Sarco-Nutrineck The aim of this ancillary study is to collect data on prevalence of low muscle mass in this population, treatment outcomes and survival.
Study measures:
At baseline: body height and weight, calculated BMI. Biological parameters: albumin, orosomucoid, transthyretin, CRP Daily - during the treatment period: weight Weekly - during the treatment period: albumin, orosomucoid, transthyretin, CRP. The Nutritional and inflammatory status score will be calculated.
Clinical criteria on the requirement of enteral nutrition (or need for artificial nutrition) in case of weight loss persisting at least for three days during radiotherapy:
The aim of this study is to investigate whether nutritional screening on admission can be used to determine risk levels for adverse clinical events and treatment outcome ( full treatment administration) in head and neck cancer and to propose a risk stratification based on nutritional screening before radiotherapy or concomitant chemo radiotherapy.
tube (NGT) will be placed according to the following procedure: The weight will be assessed on daily basis and will be compared to the figure at baseline, before treatment. If the weight loss is superior to 2 kg, the patient will consult a radiotherapist who will perform a physical examination, a nutritional assessment (history, appetite change, taste, quantity and quality of oral food intake, medication, details regarding weight change and BMI). In addition to dietary counselling and oral supplementation, If indicated, analgesic drugs and or treatment of associated mucositis will be prescribed.
In case of persisting weight loss or severe dysphagia or no oral solid food intake, a nasogastric tube (NGT) will be placed by a nurse and a personalized nutritional counselling by a dietician will be organized.
Biological exams will be done according to our local practice and standard, and the results will be analyzed to assess the safety. Regular clinical exams will be realized. All adverse events will reported according to the common terminology criteria for adverse events scale.
Follow-up period. The patients will benefit from a clinical exam, height, weight, BMI, biological exam (including albumin, orosomucoid, transthyretin, CRP) one month after the end of the treatment, and then at three months and at twelve months, late toxicities will be recorded.
The aim of this study is to investigate whether nutritional screening on admission can be used to determine risk levels for adverse clinical events and treatment outcome (full treatment administration) in head and neck cancer and to propose i) isk stratification based on nutritional screening before radiotherapy or concomitant chemo radiotherapy ii) decisional algorithm on placement of a NGT
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Rouen, France, 76038
- Centre Henri Becquerel
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males or females older than 18 years
- Performance Status 0 or 1 or 2
- Locally advanced head and neck cancer treated with a curative intent treatment consisting of either concomitant chemo-radiotherapy or adjuvant radiation therapy or adjuvant chemo-radiotherapy.
- Signed Informed Consent
Exclusion Criteria:
- Other cancer or previous cancer within 2 years or evolutive cancer
- Performance Status 3 or 4
- NGT or PEG at screening period
- Any legal, social, psychological reasons that could jeopardize the patient's compliance to the study constrains.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Nutrition state determination
Determination of nutritional state and inflammatory status: weekly assessment of patient's weight biological parameters (albumin, transthyretin, orosomucoid) and weekly assessment of patient's weight |
Biological assessment to determine biological and inflammatory status Quality of life questionary
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
weight
Time Frame: one year
|
Measure of weight ( in Kg)
|
one year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Nutritional status determination
Time Frame: 3 months
|
Determination of nutritional status by assessing albuminemia
|
3 months
|
|
Nutritional status determination
Time Frame: 3 months
|
Determination of nutritional status by assessing transthyretin
|
3 months
|
|
Nutritional status determination
Time Frame: 6 months
|
Determination of nutritional status by assessing albuminemia
|
6 months
|
|
Nutritional status determination
Time Frame: 6 months
|
Determination of nutritional status by assessing transthyretin
|
6 months
|
|
Nutritional status determination
Time Frame: One year
|
Determination of nutritional status by assessing albuminemia
|
One year
|
|
Nutritional status determination
Time Frame: One year
|
Determination of nutritional status by assessing transthyretin
|
One year
|
|
Inflammatory status
Time Frame: 3 months
|
Determination of inflammatory status by assessing orosomucoid
|
3 months
|
|
Inflammatory status
Time Frame: 3 months
|
Determination of inflammatory status by assessing CRP
|
3 months
|
|
Inflammatory status
Time Frame: 6 months
|
Determination of inflammatory status by assessing orosomucoid
|
6 months
|
|
Inflammatory status
Time Frame: 6 months
|
Determination of inflammatory status by assessing CRP
|
6 months
|
|
Inflammatory status
Time Frame: one year
|
Determination of inflammatory status by assessing orosomucoid
|
one year
|
|
Inflammatory status
Time Frame: one year
|
Determination of inflammatory status by assessing CRP
|
one year
|
|
BMI calculation
Time Frame: one year
|
Calculation of BMI using height and weight
|
one year
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHB 13.04
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head and Neck Cancer
-
Robert FerrisAmgenCompletedHead and Neck Cancer | Cancer of Head and Neck | Head Cancer | Neck Cancer | Neoplasms, Head and Neck | Cancer of the Head and Neck | Cancer of Neck | Upper Aerodigestive Tract Neoplasms | Neck Neoplasms | Cancer of the Head | Cancer of the Neck | UADT Neoplasms | Cancer of Head | Head Neoplasms | Head, Neck Neoplasms | Neoplasms, Head and other conditionsUnited States
-
Assiut UniversityRecruitingHead and Neck Cancer | Head and Neck Neoplasms | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and NeckEgypt
-
Mayo ClinicCompletedCancer Head Neck | Cancer Neck | Cancer, HeadUnited States
-
West China HospitalNot yet recruitingHead and Neck Cancer | Malignant Neoplasm | Advanced Head and Neck Carcinoma | Head &Amp; Neck Cancer
-
Fondazione IRCCS Policlinico San Matteo di PaviaNestle Health Science; Akern SrlCompletedHead-neck CancerItaly
-
National Cancer Institute (NCI)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
Radboud University Medical CenterUnknown
-
University of California, San FranciscoCompleted
-
Canadian Cancer Trials GroupCanadian Institutes of Health Research (CIHR)RecruitingAdvanced Head and Neck CancerCanada
-
Centre Oscar LambretCompletedEpidermoid Head and Neck CancerFrance
Clinical Trials on weekly assessment of patient's weight
-
University Hospital, BordeauxCompletedSubstance-Related Disorders | Addictive BehaviorFrance
-
Foundation for Prader-Willi ResearchPrader-Willi Syndrome Association USACompleted
-
Palo Alto Veterans Institute for ResearchCarevive Systems, Inc.CompletedQuality of Life | Lung Cancer | Supportive CareUnited States
-
The University of Tennessee, KnoxvilleCompleted
-
Duke UniversityCompletedObesity | Overweight | Weight LossUnited States
-
Federal Research Institute of Pediatric Hematology...CompletedNeterton SyndromeRussia
-
ISPA - Instituto Universitario de Ciencias Psicologicas...Fundação para a Ciência e a TecnologiaCompletedPhysical Activity | Weight Loss | Eating Behavior | Behavior and Behavior Mechanisms | Self Esteem | Subjective Well-beingPortugal
-
Yu- Hsuan ChienCompletedTwelve Week Quantitative Weight Bearing of Resistance Training Effect on Glycemic Control and Muscle StrengthTaiwan
-
Centre hospitalier de l'Université de Montréal...Completed
-
University Hospital, MontpellierUnknownGeriatrics | Clinical PharmacyFrance